CD14启动子-159位点基因多态性与糖尿病肾病的相关性研究

者在10年和20年时,发生DN的百分率分别为13.3%和23.4%;纯合子CC基因型2型糖尿病患者发生DN的风险高于CT+TT基因型患者.结论 CD14启动子C-159T基因多态性与糖尿病的发病无关,但其中的CC纯合子基因是2型糖尿病患者进展为DN的遗传学风险因素.     

CD14基因-159C／T位点多态性对哮喘患者血浆IL-5的影响

目的探讨CD14基因-159C／T位点多态性和支气管哮喘（哮喘）的相关性及其对血浆IL-5的影响。方法选择正常对照组和哮喘组各150例,取外周血离心后,用酶联免疫吸附试验法测定血浆IL-5,用限制性片段长度多态性-聚合酶链反应方法检测CD14基因-159C／T位点多态性分布。结果对照组和哮喘组等位基因C、T分布有统计学差异（Х^2=10．82,P〈0．01）,C等位基因与哮喘相关（C／T的OR=1．73,95％CI=1．25—2．39,P〈0．01）,两组基因型（TT、CT、CO）频率分布有统计学差异（r=9．73,P〈0．01）;同组内C等位基因携带者血浆IL-5高于非携带者,以CC基因型最高;同一基因型哮喘组IL-5高于对照组。结论CD14基因启动子-159位点多态性与哮喘相关,C等位基因与血浆IL-5升高相关。     

CD14基因启动子区多态性与缺血性脑卒中及血脂的相关分析

目的探讨CD14基因启动子-159C/T-、260C/T多态性与缺血性脑卒中的相关性,并对其与血脂、脂蛋白水平的关系进行分析。方法应用PCR-RFLP的方法检测132例缺血性脑卒中患者(缺血性脑卒中组)和145例对照组的CD14基因型;同时按常规方法测定血浆脂质、脂蛋白水平。结果缺血性脑卒中组总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平明显高于对照组(P<0.05),CD14基因-159C/T多态性在两组人群中的分布差异有显著性意义(P<0.05),等位基因频率的相对风险分析发现,C等位基因携带者患缺血性脑卒中的风险是T等位基因的1.556倍(OR=1.556,95%CI:1.108~2.184),携带C等位基因的缺血性脑卒中个体血浆低密度脂蛋白胆固醇水平显著高于不携带者(P<0.05)。结论CD14基因-159C/T多态性与缺血性脑卒中的发病具有相关性,其中C等位基因是缺血性脑卒中的遗传危险因素;CD14基因-159C/T多态性可能通过影响血脂水平而影响缺血性脑卒中的发生。     

Association of promoter polymorphism of the CD14 C （-159） T endotoxin receptor gene with chronic hepatitis B

INTRODUCTION An estimated 350 million persons worldwide are infected with hepatitis B virus (HBV). Hepatitis B carriers are at risk for development of cirrhosis and hepatocellular carcinoma. Persons with chronic hepatitis B infection need life-long monito…     

CD14的基因型及血清水平与急性心肌梗死的关系

目的 研究CD14基因启动子-159C/T、-260C/T多态性各等位基因及基因型在急性心肌梗死(AMI)患者中的分布频率,初步分析其基因型及血清水平与AMI的相关性.方法 采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,检测120例AMI患者及130例正常对照组CD14的基因多态性,同时采用酶联免疫吸附试验(ELISA)检测血清CD14水平.结果 AMI组血清CD14水平显著高于对照组(P<0.01),CD14基因-159C/T多态性在AMI组和正常人群中的分布差异无显著性(P>0.05),而CD14基因-260C/T多态性在两组人群中的分布差异存在显著性(P<0.05),等位基因频率的相对风险分析发现,T等位基因携带者患AMI的风险是C等位基因的1.654倍(OR=1.654,95%CI:1.161～2.356),携带T等位基因的AMI患者血清CD14水平显著高于不携带者(P<0.05).结论 CD14基因启动子-260C/T多态性与AMI的发病具有相关性,其中T等位基因可能是AMI发病的遗传易感基因;携带T等位基因的个体可能通过促进CD14的高度表达进而增加了AMI的发病风险.     

Influence of C-159T SNP of the CD14 gene promoter on lung function in smokers

CD14, a co-receptor for endotoxin, plays a significant role in regulating the inflammatory response to this agent. The C-159T single nucleotide polymorphism (SNP) in the CD14 gene promoter is an important regulator of CD14 expression, with TT homozygotes having increased expression of CD14. This SNP has been linked to pathogenesis of asthma and with cardiovascular diseases in smokers. We hypothesize that CD14 also plays a role in the pathophysiology of COPD in smokers who are exposed to endotoxin contained in cigarette smoke as well as endotoxin derived from Gram-negative microbes colonizing their airways. To assess the effect of the C-159T SNP of the CD14 gene promoter on lung function, we recruited 246 smokers 40 years of age or older with a range of 10–156 pack-year smoking exposures. The TT genotype was associated with lower lung function in smokers with a moderate smoking history. However, the CC genotype was associated with decreased lung function in heavy smokers (>56 pack years). The effect of CC genotype on severity of COPD is analogous with the effect of this genotype in risk for asthma. CD14 may be a factor in the pathophysiology of COPD, as it is in asthma and smoking-related cardiovascular diseases.     

The -159C/T polymorphism in the promoter region of the CD14 gene is associated with advanced liver disease and higher serum levels of acute-phase proteins in heavy drinkers

BACKGROUND: Innate inflammatory responses to endotoxin (lipopolysaccharide) contribute to the development of alcoholic liver disease (ALD). A single-nucleotide polymorphism (-159C/T) in the promoter region of the gene coding for CD14 (a lipopolysaccharide receptor) could be associated with the development of ALD. We sought too investigate the relationship between the CD14/-159C/T polymorphism and advanced ALD and acute-phase protein levels in heavy drinkers. METHODS: A total of 138 heavy drinkers consecutively admitted to an Internal Medicine department were genotyped for the CD14/-159C/T polymorphism. Serum samples were analyzed for lipopolysaccharide-binding protein (LBP), soluble CD14 (sCD14), C-reactive protein (CRP), and immunoglobulin (Ig) A, IgG, and IgM. Patients with ascites or liver encephalopathy (n = 35) were classified as having advanced ALD. RESULTS: After adjusting for potential confounding variables, the CD14/-159TT genotype was positively associated with advanced ALD (odds ratio, 2.99; 95% confidence interval, 1.09-8.24, p = 0.03) and serum LBP (p = 0.01) and sCD14 (p = 0.04) levels. The CD14/-159C/T polymorphism was not associated with serum levels of CRP, IgA, IgG, or IgM. CONCLUSIONS: Our results support the notion that CD14/-159TT homozygous heavy drinkers have higher levels of the LPS-binding acute-phase proteins (LBP and sCD14) than do carriers of the CD14/-159C allele. Also, the CD14/-159TT genotype may be a risk factor for advanced ALD.     

Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk

Objective:To investigate the association between the cluster of differentiation 14(CD14)-I59C/T(rs2569190) gene polymorphism and susceptibility to acute brucellosis in an Iranian population.Methods:The study included 153 Iranian patients with active brucellosis and 128 healthy individuals as the control group.Genotyping of the CD 14 variant was performed using an amplification refractory mutation system-polymerase chain reaction method.Results:The prevalence of CD14-159 TT and CT genotypes were associated with increased risk of brucellosis[odds ratio(OR)=l.993.95%confidence interval(95%CD=1.07-3.71.P=0.03 for CT:OR=3.869.95%CI= 1.91-7.84,P=0.01 for TT genotype.Additionally,the minor allele(T) was significantly more frequently present in brucellosis patients than in controls(61%vs.45%.respectively),and was a risk factor for brucellosis(OR=3.058.95%CI= 1.507-6.315.P=0.01).Condusions:The findings provid suggestive evidence of association of the CDI4-159C/T gene polymorphism with susceptibility to acute brucellosis in the Iranian population.     

CD14启动子-260位点基因多态性对糖尿病肾病的影响

目的探讨CD14启动子-260位点基因多态性对糖尿病肾病（DN）的影响。方法应用PCR直接测序法对437例2型糖尿病（T2DM）患者（T2DM组）及145例正常者（对照组）的CD14启动子C-260T基因多态性进行分析。结果两组CD14启动子-260位点基因型分布及等位基因频率均无统计学差异（P〉0．05）;非DN与DN患者比较,其CD14启动子-260位点CC基因与CT＋TT基因有统计学差异（P〈0．05）。结论CD14启动子-260C／T基因多态性与糖尿病发病无相关性,但其CC基因是T2DM患者进展为DN的遗传学风险因素。     

Genetic contribution of the CD14 -159C/T dimorphism in the promoter region in Japanese RA

OBJECTIVE: To study the contribution of the CD14 gene to the pathogenesis of rheumatoid arthritis (RA) in Japanese patients. METHODS: CD14 genotyping was carried out at the -159C/T dimorphic site in 97 RA patients and 104 normal subjects by the PCR-RFLP (restriction fragment length polymorphism) METHOD: HLA-DRB1 genotyping was performed by the PCR-SSCP (sequence specific conformational polymorphism) method. RESULTS: The -159C/T dimorphism is not associated with whole RA or with female RA, and the results were compatible with a previous report from Germany. The -159C/T dimorphism was not associated with rheumatoid factor (RF)-positive RA, although the -159T allele tended to be associated with RF in the German report. The -159C/T dimorphism showed no association even in RA patients with the RA-susceptibility HLA-DRB1*0405. The -159T allele was prevalent in Japanese controls. CONCLUSION: The CD14 gene is very unlikely to be genetically involved in the pathogenesis of Japanese RA.     

白细胞介素13基因-1112C/T多态性与支气管哮喘患者发病及血浆总IgE水平的相关性

目的探讨白细胞介素13(IL13)基因启动子区-1112C/T多态性与支气管哮喘(简称哮喘)的相关性及对血浆总IgE水平的影响。方法将哮喘患者(100例)和健康人(100名)被分为哮喘组和对照组,用聚合酶链反应限制性片段长度多态性(PCRRFLP)方法检测哮喘组与对照组-1112位点多态性,用酶联免疫吸附法(ELISA)测定血浆总IgE水平。结果-1112位点等位基因C、T频率在两组间分布的差异具有显著性(χ2=901,P<001),等位基因T与哮喘关联[OR(T/C)=203,95%CI=127～323,P<001]。两组基因型(TT、CT、CC)频率的分布比较差异有显著性(χ2=719,P<005),其优势比OR(TT/CC)=299,95%CI=106～841(P<005);OR(CT/CC)=204,95%CI=109～381(P<005);OR(TT/CT)=146,95%CI=049～437(P>005);在哮喘组CC、CT及TT基因型患者的血浆总IgE水平分别为(204±89)kU/L、(320±108)kU/L、(376±147)kU/L,而在对照组CC、CT及TT基因型患者的血浆总IgE水平分别为(96±34)kU/L、(122±42)kU/L、(150±36)kU/L。同组内T等位基因携带者血浆总IgE水平高于非携带者;同一基因型中哮喘组总IgE水平高于对照组。结论IL13基因-1112位点多态性是影响哮喘的重要候选基因,T等位基因与哮喘关联,并可能通过增强IL13基因的表达影响血浆总IgE水平。     

Association of the -159 C --> T polymorphism in the CD14 promoter with variations in serum lipoproteins in healthy subjects.

The CD14-159 C --> T polymorphism, a single nucleotide polymorphism (SNP) at position -159 in the promoter region of the gene encoding the pattern recognition receptor CD14, has been associated with elevated plasma concentrations of soluble CD14, lowered serum immunoglobulin E, increased risk for myocardial infarction, and decreased risk for allergy and asthma. In the present study, the CD14-159 C --> T polymorphism has been investigated in order to determine its frequency and association with proinflammatory variables and lipid profile traits of 117 volunteers. The frequency of the CD14 promoter genotype as determined by polymerase chain reaction amplification-restriction fragment length polymorphism analysis was 35.0% (CC), 44.4% (CT), and 20.5% (TT), and the T allele frequency was 42.7%. Compared with the other genotypes, notably CC homozygotes, TT homozygotes were associated with lower total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B-100 (P < 0.01) concentrations in serum. However, no association was found between the investigated SNP and inflammatory mediators such as fibrinogen, interleukin-6, tumor necrosis factor-alpha, tissue factor, C-reactive protein, plasminogen activator inhibitor-1, leukotriene B4, or thromboxane B2. In conclusion, the CD14-159 C --> T polymorphism may be an important genetic trait, related to the ability of CD14 to bind and transport lipids, such as cholesterol.     

中国北方汉族CD14启动子C(-260)T基因点突变及血浆IL-6含量与冠心病的相关性

目的探讨冠心病(CHD)患者CD14启动子C(-260)T基因点突变情况及血浆IL-6含量变化与CHD的相关性。方法采集115例CHD病人和60例健康人抗凝血,用PCR-RFLP法测定CD14启动子C(-260)T基因点突变情况,ELISA法检测血浆IL-6含量。结果CHD组CD14启动子C(-260)T基因点突变频率与对照组无统计学差异(χ2=2.644,P=0.267);CHD组血浆IL-6水平高于健康对照组(t=3.553,P<0.01);CHD病人不同基因型组血浆IL-6含量无统计学差异(F=0.294,P=0.749)。结论CD14启动子C(-260)T基因多态性可能不是CHD的基因决定性危险因子,但作为炎性因子的IL-6在CHD的发生、发展中起着重要的作用,     

CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction

Background Monocyte differentiation antigen CD14 is considered an important cell-activating mediator of inflammatory responses that may result in atherosclerosis, coronary artery disease (CAD), thrombus formation, and myocardial infarction (MI). We assessed the possibility that a C → T nucleotide substitution polymorphism in the promoter (position −159) of the gene encoding CD14 constitutes a risk factor for CAD and MI. Methods Consecutive patients with significant, angiographically documented coronary stenoses but without symptoms or signs of old or acute MI constituted the group with CAD (n = 998). Consecutive patients with angiographic examination with old or acute MI constituted the group with MI (n = 793). Subjects matched with patients for age and gender but without angiographic evidence of CAD and without symptoms or signs of MI (n = 340) and a group of healthy blood donors (n = 104) served as controls. Results Genotype distributions of the −159C/T polymorphism were similar across the groups; CC:CT:TT was 26.9%:51.0%:22.1% in blood donors, 25.9%:52.0%:22.1% in matched control subjects, 27.4%:49.9%:22.7% in patients with CAD, and 29.2%:49.2%:21.6% in patients with MI. The lack of association persisted also after adjustment for the presence of conventional cardiovascular risk factors. In addition, no significant differences were found between genotype distributions of control subjects and selected subgroups of patients with CAD or MI. Conclusion These findings indicate that, in the sample of patients examined in this study, the −159C/T polymorphism of the CD14 gene is not related to CAD or MI. (Am Heart J 2002;143:971-6.)     

Common promoter polymorphism in monocyte differentiation antigen CD14 is associated with serum triglyceride levels and body mass index in non-diabetic individuals.

AIMS: Growing evidence supports the hypothesis that chronic low-grade inflammation related to innate immunity may play an important role in the pathophysiology of Type 2 diabetes mellitus (T2DM). The monocyte differentiation antigen CD14 gene (CD14) acts as the receptor for lipopolysaccharide (LPS) and augments monocyte/macrophage inflammatory responses. METHODS: We have sequenced the gene, including all exons, exon/intron boundaries, and the -1.5 kb of the 5' flanking region. Two common loci (minor allele frequency > 0.05) were genotyped in 775 T2DM patients and 316 control subjects recruited in the Korean T2DM Study. RESULTS: Eight polymorphisms, including four non-synonymous forms, were identified in CD14. No polymorphisms were found in association with T2DM. However, one common promoter SNP (-260T>C) was significantly associated with both the serum triglyceride level (TG) and body mass index (BMI) in non-diabetic control subjects. Individuals who carried the minor allele (C) had higher TG levels (1.65 +/- 0.81 vs. 1.46 +/- 0.80 mmol/l; P = 0.0007) and BMI (23.96 +/- 3.00 vs. 23.28 +/- 3.22 kg/m(2); P = 0.04) as compared with subjects carrying T/T genotypes. CONCLUSION: Our data suggest that lipid metabolism and obesity, important pathophysiological elements of T2DM and the metabolic syndrome, are regulated by complex mechanisms that include the CD14 gene polymorphism-mediated genetic propensity to non-specific inflammatory responses.     

CD14及Toll样受体4基因多态性与大肠癌的相关性研究

目的探讨我国湖北汉族人Toll样受体（TLR）4基因Asp299Gly和CD14 C-260T基因多态性分布与大肠癌的相关性。方法采用聚合酶链反应限制性片段长度多态性（PCR—RFLP）方法，检测110例大肠癌患者及160例正常对照者TLR4基因Asp299Gly及CD14 C-260T基因型及等位基因频率的分布。结果大肠癌组CD14 C-260T基因型与正常对照组比较，差异有统计学意义（P〈0．05）。正常对照组CC基因型的频率为15．6%，明显低于大肠癌组的31．8％（P=0．0027，OR=0．3968，95％CI=0．2209～0．7129）；正常对照组中CT基因型的频率为48．1％，明显高于大肠癌组的30．9％（P=0．0056，OR=2．074，95%CI=1．246～3．452）。所有样本中均未发现TLR4基因Asp299Gly的突变型。结论CD14 C-260T基因多态性与中国湖北汉族大肠癌显著相关，而TLR4基因Asp299Gly多态性与大肠癌无关。